Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Reminds investors of the upcoming August 4, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Grail, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL ) common stock between May 13, 2025 and February 19, 2026 , inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR GRAIL INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On February 19, 2026, Grail announced that the “primary endpoint of statistically significant Stage III-IV [cancer] reduction was not observed” in its NHS-Galleri Trial due, in part, to “probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately.” On this news, Grail’s stock price fell $51.32, or 50.5%, to close at $50.21 per share on February 20, 2026, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the confidence management provided in light of the “Positive Top-Line Results” from the trial’s first screening round and the Pathfinder studies was misplaced and ignored potential trendlines in unreleased topline data and other information learned since the inception of the study that suggested three years would be le...